deltatrials

Non-alcoholic steatohepatitis Trials in Baltimore, United States

Conditions / Non-alcoholic steatohepatitis / Baltimore, United States

Non-alcoholic steatohepatitis has been the subject of sustained clinical investigation across multiple research sites.

12 total trials for this combination

Showing top 10 of 12 trials

Trials

NCT ID Title Status Phase
NCT02686762 Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis COMPLETED PHASE2
NCT05016882 Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH) COMPLETED PHASE2
NCT03987451 A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage COMPLETED PHASE2
NCT00678587 Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures TERMINATED PHASE3
NCT02970942 Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis. COMPLETED PHASE2
NCT03421431 A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis COMPLETED PHASE2
NCT04822181 Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) ACTIVE_NOT_RECRUITING
NCT02787304 Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH) TERMINATED PHASE2
NCT04378010 A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH TERMINATED PHASE2
NCT02960204 Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension COMPLETED PHASE2

Related Pages